Parkinson’s disease: Prexton Therapeutics starts phase 1 clinical trial
First clinical trial with an mGluR4 positive allosteric modulator, a first-in-class compound for treating Parkinson’s disease, will assess safety and tolerability. Prexton Therapeutics, a biopharmaceutical company developing novel therapeutics for the treatment of
CNS conditions, today announces the launch of a phase 1 clinical trial. Prexton Therapeutics is the first company to enter in man clinical trials with an mGluR4 positive allosteric modulator. The trial should be complete by mid 2016, with results expected in August 2016.